Gp100:209-217(210M) peptide vaccine(National Cancer Institute)(Gp100:209-217(210M) peptide vaccine(National Cancer Institute))

概要

基本信息

药物类型

通用抗原疫苗、合成肽疫苗、治疗性疫苗

别名-

靶点

gp100

作用方式

抑制剂

作用机制

gp100抑制剂(黑素细胞蛋白PMEL抑制剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病眼部疾病+ [1]

在研适应症-

非在研适应症

复发性黑色素瘤皮肤黑色素瘤转移性黑色素瘤+ [1]

原研机构

National Cancer Institute

在研机构-

非在研机构

University of Southern California

National Cancer Institute

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Gp100:209-217(210M) peptide vaccine(National Cancer Institute) 相关的临床试验

NCT00357461

/ Withdrawn临床2期

A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma

RATIONALE: Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Vaccines made from gp100 peptides may help the body build an effective immune response to kill tumor cells. Giving ipilimumab together with vaccine therapy may be an effective treatment for melanoma.
PURPOSE: This randomized phase II trial is studying ipilimumab and vaccine therapy to see how well they work compared to ipilimumab alone in treating patients with previously treated stage IV melanoma.

开始日期2006-05-01

申办/合作机构

Bristol Myers Squibb Co.

[+1]

NCT00334776

/ Completed临床2期IIT

A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.

开始日期2003-10-01

申办/合作机构

University of Southern California

[+1]

NCT01989559

/ Completed临床1期IIT

A Pilot Study to Assess the Immunologic Response to Booster Vaccination With a Modified gp100 Melanoma Peptide (209-2M) Vaccine in Previously Vaccinated HLA-A2.1+ Patients With Melanoma

This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.

开始日期2002-10-01

申办/合作机构

National Cancer Institute

100 项与 Gp100:209-217(210M) peptide vaccine(National Cancer Institute) 相关的临床结果

登录后查看更多信息

100 项与 Gp100:209-217(210M) peptide vaccine(National Cancer Institute) 相关的转化医学

登录后查看更多信息

100 项与 Gp100:209-217(210M) peptide vaccine(National Cancer Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Gp100:209-217(210M) peptide vaccine(National Cancer Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤黑色素瘤	临床2期	美国	University of Southern California	2003-10-01
转移性黑色素瘤	临床2期	美国	University of Southern California	2003-10-01
葡萄膜黑色素瘤	临床2期	美国	University of Southern California	2003-10-01
复发性黑色素瘤	临床2期	美国	National Cancer Institute	2003-04-01